Market Overview:
The global gene delivery systems market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of chronic diseases, rising demand for novel therapeutics, and technological advancements in the field of gene delivery systems. Based on type, the global gene delivery systems market is segmented into viral gene delivery system, non-viral gene delivery system, and combined hybrid system. The viral gene delivery system segment dominates the market owing to its high efficiency and specificity in delivering genes into cells. Based on application, the global gene delivery systems market is segmented into infectious diseases, oncology, ophthalmology, urology diabetes mellitus (DM), central nervous system (CNS), and others. The infectious diseases segment accounts for the largest share of the global Gene Delivery Systems Market due to increasing incidence of infections across globe coupled with rising demand for novel therapeutics options for their treatment.
Product Definition:
Gene delivery systems are used to deliver genes into cells. The purpose of gene delivery is to introduce new genetic information into a cell. Gene delivery can be used to treat diseases or disorders, or to create genetically modified organisms.
Viral Gene Delivery System:
Viral gene delivery system is a complex of nucleic acid construct, which can deliver gene to the target cell by infecting the host. Viral particles are capable to carry genetic material (DNA or RNA) of any size and shape. The mechanism used by viruses for infection is that they enter the host cell through the outer membrane and release their payload inside a cytoplasmic space.
Non-viral Gene Delivery System:
Non-viral gene delivery system is a complex of material that can deliver genetic information to the target cells. It includes liposomes, nanoparticles, polymers & micelles, dendrimers & nanoviscous fluids and other such systems. The most commonly used method for gene delivery is by using DNA plasmid or RNA virus which contains the genetic information of interest.
Application Insights:
The other application segment includes cardiology, endocrinology, neurology and others. The use of gene therapy for treating diseases such as Parkinson¢â‚¬â„¢s disease, Alzheimer¢â‚¬â„¢s disease and spinal cord injuries have been reported in the literature. Hence, this segment is anticipated to witness lucrative growth during the forecast period owing to increasing research activities for developing effective delivery systems.
Oncology accounted for a significant share in 2015 due to extensive usage of viral vector-based gene transfer systems such as retroviral vectors and adenoviral vectors for cancer treatment. Moreover, non-viral gene delivery system based on shRNA technology is also gaining popularity due to its ease of use and potential applications in future therapies without the need for genetic modification of cells or introduction of foreign genes into them which may lead to safety concerns regarding side effects or unanticipated outcomes associated with it over time.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of key players and well-established healthcare infrastructure. Moreover, increasing R&D investments by companies and government for developing novel gene delivery systems is expected to drive growth over the forecast period. For instance, in May 2018, Intuitive Surgical invested more than USD X million for research & development activities related to surgical technologies such as da Vinci Surgical System and Lumenis (knee) Hybrid System.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising disposable income coupled with growing awareness regarding advanced treatment options among patients suffering from various chronic diseases such as cancer, diabetes, cardiovascular disorders & etc. In addition it will boost demand for cost-effective therapies that require less time or intervention which are suitable for remote patient monitoring thereby driving regional market growth during the forecast period 8).
Growth Factors:
- Increasing demand for gene therapies for the treatment of various diseases
- Growing number of public and private sector initiatives to support R&D in gene therapy field
- Rising prevalence of chronic diseases that can be treated with gene therapies
- Technological advancements in the field of gene delivery systems
- Growing awareness about the benefits of gene therapies among healthcare professionals and patients
Scope Of The Report
Report Attributes
Report Details
Report Title
Gene Delivery Systems Market Research Report
By Type
Viral Gene Delivery System, Non-viral Gene Delivery System, Combined Hybrid System
By Application
Infectious Diseases, Oncology, Ophthalmology, Urology, Diabetes, CNS, Others
By Companies
Novartis, Amgen, Oxford BioMedica, SIBIONO, Shanghai Sunway Biotech, Roche, Pfizer, Bayer, Johnson & Johnson, Becton Dickinson, AstraZeneca, Baxter, HSCI, Epeius Biotechnologies
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Gene Delivery Systems Market Report Segments:
The global Gene Delivery Systems market is segmented on the basis of:
Types
Viral Gene Delivery System, Non-viral Gene Delivery System, Combined Hybrid System
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Diseases, Oncology, Ophthalmology, Urology, Diabetes, CNS, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Amgen
- Oxford BioMedica
- SIBIONO
- Shanghai Sunway Biotech
- Roche
- Pfizer
- Bayer
- Johnson & Johnson
- Becton Dickinson
- AstraZeneca
- Baxter
- HSCI
- Epeius Biotechnologies
Highlights of The Gene Delivery Systems Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Viral Gene Delivery System
- Non-viral Gene Delivery System
- Combined Hybrid System
- By Application:
- Infectious Diseases
- Oncology
- Ophthalmology
- Urology
- Diabetes
- CNS
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gene Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gene delivery systems are a way to deliver genes into cells. This can be done in a number of ways, including using viruses, bacteria, and other small particles.
Some of the major players in the gene delivery systems market are Novartis, Amgen, Oxford BioMedica, SIBIONO, Shanghai Sunway Biotech, Roche, Pfizer, Bayer, Johnson & Johnson, Becton Dickinson, AstraZeneca, Baxter, HSCI, Epeius Biotechnologies.
The gene delivery systems market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gene Delivery Systems Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gene Delivery Systems Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gene Delivery Systems Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gene Delivery Systems Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gene Delivery Systems Market Size & Forecast, 2020-2028
4.5.1 Gene Delivery Systems Market Size and Y-o-Y Growth
4.5.2 Gene Delivery Systems Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Viral Gene Delivery System
5.2.2 Non-viral Gene Delivery System
5.2.3 Combined Hybrid System
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Infectious Diseases
6.2.2 Oncology
6.2.3 Ophthalmology
6.2.4 Urology
6.2.5 Diabetes
6.2.6 CNS
6.2.7 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gene Delivery Systems Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gene Delivery Systems Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Viral Gene Delivery System
9.6.2 Non-viral Gene Delivery System
9.6.3 Combined Hybrid System
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Infectious Diseases
9.10.2 Oncology
9.10.3 Ophthalmology
9.10.4 Urology
9.10.5 Diabetes
9.10.6 CNS
9.10.7 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Viral Gene Delivery System
10.6.2 Non-viral Gene Delivery System
10.6.3 Combined Hybrid System
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Infectious Diseases
10.10.2 Oncology
10.10.3 Ophthalmology
10.10.4 Urology
10.10.5 Diabetes
10.10.6 CNS
10.10.7 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Viral Gene Delivery System
11.6.2 Non-viral Gene Delivery System
11.6.3 Combined Hybrid System
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Infectious Diseases
11.10.2 Oncology
11.10.3 Ophthalmology
11.10.4 Urology
11.10.5 Diabetes
11.10.6 CNS
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Viral Gene Delivery System
12.6.2 Non-viral Gene Delivery System
12.6.3 Combined Hybrid System
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Infectious Diseases
12.10.2 Oncology
12.10.3 Ophthalmology
12.10.4 Urology
12.10.5 Diabetes
12.10.6 CNS
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Viral Gene Delivery System
13.6.2 Non-viral Gene Delivery System
13.6.3 Combined Hybrid System
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Infectious Diseases
13.10.2 Oncology
13.10.3 Ophthalmology
13.10.4 Urology
13.10.5 Diabetes
13.10.6 CNS
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gene Delivery Systems Market: Competitive Dashboard
14.2 Global Gene Delivery Systems Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Amgen
14.3.3 Oxford BioMedica
14.3.4 SIBIONO
14.3.5 Shanghai Sunway Biotech
14.3.6 Roche
14.3.7 Pfizer
14.3.8 Bayer
14.3.9 Johnson & Johnson
14.3.10 Becton Dickinson
14.3.11 AstraZeneca
14.3.12 Baxter
14.3.13 HSCI
14.3.14 Epeius Biotechnologies
